We recently proposed a possible stereoselective activation by lansoprazole of CYP2C9-catalyzed tolbutamide hydroxylation, as well as stereoselective inhibition of several P450
Introduction
The cytochrome P450s (P450s) are involved in the metabolism of both endogeneous compounds and xenobiotics, and are responsible for many metabolism-based drug interactions. Substrates for the P450s include a variety of clinically useful drugs, pesticides, carcinogens, and steroids. In most cases, the metabolism of these agents can be described using the Michaelis-Menten equation to yield estimates of K m and V max . However, some P450 enzymes do not proceed with typical Michaelis-Menten kinetics. Evidence of enzyme activation, autoactivation, partial inhibition, substrate inhibition, and biphasic saturation curves is common (Korzekwa et al., 1998) . These phenomena confound the accurate in vitro determination of kinetic parameters and thus the prediction of drug interactions in vivo (Houston and Kenworthy, 2000) .
Although reactions involving atypical kinetics are most commonly associated with CYP3A4 (Shou et al., 1994; Galetin et al., 2002) , they have also been noted with CYP2C9.
CYP2C9 is prone to both activation and inhibition effects in drug-interaction studies.
Substrate auto-and heteroactivation (Korzekwa et al., 1998; Hutzler et al., 2001a; Hutzler et al., 2002; Hutzler et al., 2003; Hummel et al., 2004) , substrate inhibition (Lin et al., 2001) , and biphasic kinetics (Korzekwa et al., 1998; Hutzler et al., 2001a) observed for CYP2C9 might be explained by different binding domains for substrates and modifiers within the enzyme-active site. The crystal structure indicates that multiple substrates/ligands may be bound to CYP2C9 simultaneously, which is consistent with reports that suggest a 'two-site model' for CYP2C9 activity (Hutzler et al., 2001a; Williams et al., 2003) .
Lansoprazole at therapeutic concentrations is metabolized, mainly by CYP2C19 and CYP3A4, to its hydroxy and sulfone metabolites, respectively, and is also metabolized by CYP2C9 to hydroxylansoprazole (Kim et al., 2002; Kim et al., 2003) . Recently, we found This article has not been copyedited and formatted. The final version may differ from this version. activates, suggesting that lansoprazole may cause activation by binding in the active site of CYP2C9. This scenario is analogous to that of dapsone and quinidine, which activate CYP2C9-mediated 4'-hydroxylation of flurbiprofen (Korzekwa et al., 1998 ) and CYP3A4-mediated 5'-methylhydroxylation of meloxicam (Ludwig et al., 1999) , respectively.
A number of reports have addressed the activation of P450-catalyzed oxidative metabolism, but none has described enantioselectivity in P450 activation. The present study evaluated the selectivity of lansoprazole enantiomers on CYP2C9 activation, using different CYP2C9 probe substrates. We also characterized the enzyme kinetics of activation of CYP2C9-mediated metabolism, and the effects of CYP2C9 substrates on lansoprazole metabolism.
This article has not been copyedited and formatted. The final version may differ from this version. (Manchester, UK). All reagents were of analytical or HPLC grade. Hydroxylansoprazole was the generous gift of Dr. Ichiro Ieiri. Individual R-and S-lansoprazole enantiomers were separated by chiral semi-preparative HPLC on a Chiralpak AS column (10 µm, 4.6 × 250 mm; Daicel Chemical Co., Tokyo, Japan), as described by Katsuki et al. (1996) . Microsomes were prepared by differential centrifugation of liver homogenates, as described previously (Shin et al., 1999) . Human recombinant CYP2C9 (Supersomes ® ) were purchased from BD Gentest Co. (Woburn, MA).
Human Liver Microsomes and

P450 Reaction Conditions:
Briefly, each incubation was performed with 0.5 mg/ml pooled human liver microsomes (HL-10, 14, and 18) in 50 mM phosphate buffer, pH 7.4, at a final volume of 0.25 ml. The incubation mixtures containing microsomes, CYP2C9 probe substrates, and effector (lansoprazole, 1-100 µM) were pre-incubated for 5 min at 37 °C.
Substrates were used at concentrations approximately equal to their respective K m values: 15 µM for diclofenac, 50 µM for phenytoin, 50 µM for tolbutamide, and 5 µM for S-warfarin.
After preincubation, reactions were initiated at 37 °C by addition of the NADPH-generating This article has not been copyedited and formatted. The final version may differ from this version. system (3.3 mM G6P, 1.3 mM β-NADP + , 3.3 mM MgCl 2 , and 1.0 unit/ml G6PDH) and stopped after the specified time by placing the incubation tubes on ice and adding 100 µl of either ice-cold acetonitrile or 10% perchloric acid, depending on the reaction, as described previously (Bourrie et al., 1996; Shin et al., 1999 , Kim et al., 2003 . Incubation mixtures were centrifuged at 20,000g for 10 min at 4 °C, and aliquots of the supernatants were analyzed by HPLC.
Incubations using 20 pmol P450/ml isolated from baculovirus-infected insect cells expressing CYP2C9 were also performed using CYP2C9 probe substrates as above. In the experiments examining the effects of phenytoin on lansoprazole hydroxylation, the phenytoin concentrations ranged from 0 to 200 µM, and the lansoprazole concentrations ranged from 0 to 50 µM. Reactions were stopped by the addition of 0.1 ml of cold acetonitrile. All other conditions were as described above.
All incubations were performed in duplicate, and the mean values were used for analysis.
Measurement of Reaction Products:
HPLC assays similar to those previously described (Bourrie et al., 1996; Shin et al., 1999; Kim et al., 2003) were used to quantify products of CYP2C9-mediated reactions. The reactions investigated were: diclofenac 4-hydroxylation, phenytoin 4-hydroxylation, tolbutamide 4-methylhydroxylation, S-warfarin 7-hydroxylation, and lansoprazole 5-hydroxylation. The HPLC system consisted of a model 307 pump, a model 234 autoinjector, and a model 118 UV/VIS detector (Gilson Co., Villiers Le Bel, France). The Unipoint ® analysis system (Gilson Co.) was used to calculate analyte concentrations from peak area ratios.
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where ν is the velocity of the reaction at substrate concentration S, V max is the maximum velocity of the enzyme, and K m is the substrate concentration at which the reaction velocity is 50% of V max .
To quantify the activation of CYP2C9-catalyzed phenytoin 4-hydroxylation, we used a two-site binding model including an activator, as described previously by Korzekwa et al. (1998) . The velocity of phenytoin hydroxylation in the presence of activator, R-lansoprazole, (2) where S is the substrate (phenytoin), B is the effector (R-lansoprazole), V max and K m are kinetic constants for substrate metabolism, K B is the binding constant for the effector, α is the change in K m resulting from effector binding, and β is the change in V max from effector binding. For activation, α < 1 and/or β >1.
The apparent enzyme inhibition or activation parameters of lansoprazole enantiomers (IC 50 or EC 50 ) were determined from a nonlinear least square regression analysis of the bestfit enzyme inhibition model and enzyme kinetic model (Segel, 1975) 
Results and Discussion
Although many studies have demonstrated activation of P450-catalyzed metabolism (i.e., Shou et al., 1994 , Hutzler et al., 2002 , none have demonstrated enantioselective activation of P450 isoforms. In this report, we describe the stereoselective activation of human liver microsomal CYP2C9 by lansoprazole. R-lansoprazole (100 uM) activated CYP2C9-catalyzed tolbutamide 4-methylhydroxylation (140% of control, EC 50 of 19.9 µM) and phenytoin 4-hydroxylation (550% of control, EC 50 of 30.2 µM). S-lansoprazole, however, inhibited tolbutamide hydroxylation (IC 50 54.0 µM), and had no effect on phenytoin hydroxylation (Fig. 1A and 1B) . Stereoselectivity of activation has been reported for Phase II enzyme activity; the R-isomer of zileuton competitively activates the glucuronidation of the S-isomer in vitro (Sweeny and Nellans, 1992) . The activation of phenytoin hydroxylation by R-lansoprazole was also observed with recombinant human CYP2C9. R-Lansoprazole (100 µM) caused an eight-fold increase in phenytoin 4-hydroxylation, with an EC 50 of 16.2 µM ( Fig. 2A) , indicating that the CYP2C9 isoform is involved in the microsomal activation reaction. However, the activation of tolbutamide hydroxylation by R-lansoprazole was not observed in recombinant CYP2C9, confirming previous reports that many of these kinetic events are expression system-dependent (Ekins et al., 1998) .
The effect of R-lansoprazole on the kinetics of phenytoin 4-hydroxylation by recombinant human CYP2C9 was further investigated (Fig. 3) . In the absence of Rlansoprazole, K m and V max for phenytoin hydroxylation were 20.5 µM and 0.024 pmol/min/pmol P450, respectively. The V max of phenytoin hydroxylation activity increased with increasing R-lansoprazole concentrations, and the K m decreased (Table 1) . Kinetic parameters for phenytoin metabolism were also estimated using a two-site enzyme kinetic This article has not been copyedited and formatted. The final version may differ from this version. (Korzekwa et al., 1998) . As observed for quinidine (Ludwig et al., 1999 ) or 7,8-benzoflavone (Shou et al., 1994 metabolism by CYP3A4 and for dapsone metabolism by CYP2C9 (Korzekwa et al., 1998) , R-lansoprazole is also a substrate for the enzyme that it activates. We investigated the effect of phenytoin on hydroxylansoprazole formation by CYP2C9; neither had a significant effect, generating velocity curves similar to that seen with R-lansoprazole alone (Fig. 4A) . V max values for lansoprazole hydroxylation ranged from 0.038 to 0.041 pmol/min/pmol P450, while K m values ranged from 5.8 to 7.3 µM. These results suggest that both substrates (or substrate and activator) can be present simultaneously in the enzyme-active site (Shou et al., 1994; Hutzler et al., 2001a) . Indeed, its crystal structure also indicates that CYP2C9 may have the capacity to bind multiple substrates simultaneously during catalysis (Williams et al., 2003) . Meanwhile, hydroxylansoprazole formation from S-lansoprazole some inhibited by addition of phenytoin in a concentration dependent manner (Fig. 4B) , suggesting that S-lansoprazole and phenytoin could competitively bind in the same enzyme-active site.
In this study, additional R-lansoprazole effects on CYP2C9-mediated metabolism in human liver microsomes were substrate specific. S-warfarin hydroxylation was inhibited (IC 50 67.9 µM), but diclofenac 4-hydroxylation was unaffected (Fig. 1C and 1D ). The substrate dependency of lansoprazole effects on CYP2C9-mediated metabolism was also observed with recombinant human CYP2C9. R-Lansoprazole didn't show stereoselective activation on S-warfarin hydroxylation and diclofenac hydroxylation in contrast to phenytoin hydroxylation (Fig. 2) . Substrate-dependent effects have been extensively studied in CYP3A4, and have been attributed to action at multiple and cooperative binding sites within (Korzekwa et al., 1998; Galletin et al., 2002; Egnell et al., 2003) .
While we have demonstrated the stimulation of phenytoin metabolism by R-lansoprazole in vitro, similar activations have been shown to occur in vivo. Tang et al. (1999) reported that the decrease in plasma concentrations of diclofenac observed when combined with quinidine treatment in the monkey reflected an increased hepatic clearance of the former drug, presumably resulting from the stimulation of CYP3A4-catalyzed oxidative metabolism.
Additionally, Hutzler et al. (2001b) reported that apparent oral clearance of flurbiprofen was increased by ~11% after 7 days of treatment with 100 mg dapsone, consistent with the hypothesis that dapsone cooperatively enhances the metabolism of flurbiprofen in vivo. The in vivo activation potential of R-lansoprazole on phenytoin metabolism remains to be evaluated.
In conclusion, lansoprazole activates CYP2C9-mediated metabolism in a stereo-and substrate-specific manner, consistent with a model in which R-lansoprazole and substrate may fit into the active site simultaneously. In addition, our results show that lansoprazole enantiomers have different drug-interaction potentials for CYP2C9-mediated metabolism. In vitro drug-interaction studies with enantiomers, in addition to racemic mixtures, should be considered in the development of chiral drugs.
